An age-period-cohort analysis for prevalence of common psychiatric disorders in Japan, 1999–2017

Okui Tasuku
Medical Information Center, Kyushu University Hospital

<http://hdl.handle.net/2324/4149945>

出版情報 : Social psychiatry and psychiatric epidemiology, pp.1–10, 2020–11–22. Springer International
バージョン :
権利関係 :

Title :

An Age-Period-Cohort Analysis for Prevalence of Common Psychiatric Disorders in Japan, 1999–2017

Author:

Tasuku Okui¹ (PhD, MPH)

Affiliation:

1) Medical Information Center, Kyushu University Hospital, Fukuoka city, Japan.

Running title:

Japan Common Psychiatric Disorders Prevalence

Corresponding Author:

Tasuku, Okui

Address: 〒812-8582 Maidashi3-1-1 Higashi-ku Fukuoka city Fukuoka prefecture, Japan

Telephone: +81-092-642-5882

Email: task10300@gmail.com

Abstract

Purpose: This study aimed to analyze the prevalence of common psychiatric disorders in Japan via an age-period-cohort (APC) analysis.

Methods: Data were used on the prevalence of schizophrenia and schizotypal and delusional disorders, mood [affective] disorders (mood disorders, hereafter), and neurotic, stress-related, and somatoform disorders from the 1999–2017 Patient Survey in Japan. The age group was defined as 20–89 years with five-year increments; the cohort was assigned for each age group of each year with a one-year shift. A Bayesian APC analysis was used to decompose changes in prevalence into three effects: age, period, and cohort.

Results: The APC analysis revealed that the peaks of age effect varied among sexes and diseases. The period effects for all the diseases showed increasing trends over the analyzed years. Although the cohort effect for prevalence of schizophrenia and schizotypal and delusional disorders increased until the 1960s, it decreased afterwards. On the other hand, the cohort effects for prevalence of mood disorders and neurotic, stress-related, and somatoform disorders increased from around the 1950s, and it indicates the prevalence increased particularly in young ages over the years. Also, the trends of each effect were relatively similar between mood disorders and neurotic, stress-related, and somatoform disorders.

Conclusion: Increase in public awareness and psychological stress associated with change in social environment is thought to affect the period and cohort effects on prevalence of mood disorders and neurotic, stress-related, and somatoform disorders.

Keywords: Age-period-cohort analysis, the Patient Survey in Japan, Psychiatric Disorders, Japan, Prevalence

1. Introduction

The number of patients with psychiatric disorders has increased over the years in Japan. According to the Patient Survey in Japan [1], the estimated number of patients with mental and behavioral disorders increased from 1.82 million in 1999 to 3.48 million in 2017. Specifically, patients with mood [affective] disorders increased from 0.44 million in 1999 to 1.28 million in 2017, and patients with neurotic, stress-related, and somatoform disorders increased from 0.42 million in 1999 to 0.83 million in 2017. Accordingly, the national medical expenses of mental and behavioral disorders amounted to 1.91 trillion yen in 2017 [2]. If diseases of the nervous system, such as Alzheimer's, are taken into account as psychiatric disorders, the number of patients and/or national medical expenses would become even larger. Furthermore, it is important to not only consider the direct costs of the diseases but also the indirect costs such as the decrease of labor productivity or unemployment, and social cost associated with the psychiatric disorders as well [3].

However, epidemiological studies that have previously investigated the trend of psychiatric disorders are few in number when compared to other major diseases such as cancer or cardiovascular diseases in Japan [4,25]. Although some epidemiological studies have investigated the prevalence of common psychiatric disorders in Japan [5,6], a study using nationwide and/or time series data has not yet been conducted. It is interesting to note that even data from the Patient Survey that routinely investigates the number of patients with psychiatric disorders across Japan, information on the trend of prevalence over various age groups and over the cohorts have not been analyzed. The age-period-cohort analysis (APC) is an analytical method often used for investigating the trend of a disease [7], and it decomposes the statistics of various age groups over the years into age, period, and cohort effects. The APC analysis is commonly used in the public health domain to analyze trends in the incidence or mortality of a disease, particularly for cancer or cardiovascular diseases in Japan [8,9]. Although there are some studies that have used APC analysis for analyzing the trend of mental illnesses in other countries [10,11,12], an APC analysis for psychiatric disorders has not yet been conducted in Japan. By analyzing the Patient Survey data in Japan using the APC model, the effects of age groups and/or birth cohorts on the prevalence of psychiatric disorders can, thereby, be estimated.

This study analyzed the trends surrounding the prevalence of common psychiatric disorders using the APC analysis of data collected by the Patient Survey in Japan.

2. Methods

Data from the Patient Survey in Japan [1] were used. The Patient Survey tallies the number of patients who visit a hospital or clinic at sites throughout Japan.

The hospitals and clinics that are surveyed are randomly chosen because the number of medical institutes is huge in Japan, whereas hospitals having >500 beds are totally surveyed. Medical institutes across all of Japan are stratified based on factors, such as the region and type of the institute, and stratified random sampling is used to select the medical institutes surveyed [13]. Hospitals are stratified based on regions, type of hospitals, and bed size, whereas clinics are stratified based on prefectures, departments, and with or without bed [13].

The Patient Survey is conducted once every 3 years. The estimated total number of patients was calculated on the basis of the number of outpatients and hospitalized patients in the Survey, and open to the public. The data for the estimated total number of patients from the seven Patient Surveys conducted from 1999 to 2017 were used for analysis.

The estimated number of patients in the survey included those with schizophrenia and schizotypal and delusional disorders, mood [affective] disorders (mood disorders, hereafter), and neurotic, stress-related, and somatoform disorders. The ICD10 code for schizophrenia and schizotypal and delusional disorders was F20–F29; for mood disorders, it was F30–F39; and for neurotic, stress-related, and somatoform disorders, it was F40–F48. The population statistics data of sex and age group were obtained from the Vital Statistics [14], and used as the denominator in the calculation of prevalence for each sex, age group, year, and disease.

The statistical analysis portion of this study included calculations for the prevalence of disorders in the patients by sex. Additionally, age-adjusted prevalence was calculated by sex for each type of disease. The age-adjusted prevalence of each disease was calculated for each combination of sex and period using the 1999 population of men as the standard population. The Bayesian APC model whose outcome value follows Poisson

distribution was used for the analysis [7]. The estimated number of patients in each age group of each year was used as the outcome value, and the corresponding number of total population was used as the offset term for the APC model. For the Bayesian prior distribution of each age, period, and cohort effect, random walk of the first order was used to identify the parameters. Age groups were defined in the data as five-year units from 20–24 years to 85–89 years. The cohort used for the APC analysis was assigned by one-year shifts; that is, the generation aged 85–89 years in 1999 was grouped into the first cohort. The most recent born cohort covered the generation aged 20–24 years in 2017. Statistically significance difference between two time points in each age, period, cohort effect was examined based on whether 95% Bayesian credible intervals overlap between the two time points. If the 95% Bayesian credible intervals of two time points of an effect do not overlap, it indicates a statistically significant difference between the two time points. To estimate the parameters, we used the Hamiltonian Monte Carlo method [15]. All statistical analyses were conducted using R software version 3.5.1 [16].

Results

Table 1 shows the estimated number of patients with schizophrenia and schizotypal and delusional disorders, mood disorders, and neurotic, stress-related, and somatoform disorders by age group in men and women.

Table 2 shows the number of patients with diagnoses schizophrenia and schizotypal and delusional disorders, mood disorders, and neurotic, stress-related, and somatoform disorders by age group per 1,000 persons in men and women. For men, although the prevalence of patients with schizophrenia and schizotypal and delusional disorders both increased and decreased in all age groups over the analyzed periods, the prevalence specifically increased from 1999 to 2017 in the age group consisting of those aged 40 years or older. The prevalence of patients with mood disorders increased in all age groups over the analyzed periods. Prevalence of patients with neurotic, stress-related, and somatoform disorders also increased in most of the age groups over the analyzed periods. For women, the prevalence of patients with schizophrenia and schizotypal and delusional disorders increased from 1999 to 2017 in the age group consisting of those aged 50 years old or older. The prevalence of

patients with mood disorders and neurotic, stress-related, and somatoform disorders increased in all age groups over the analyzed periods. It is noted that the prevalence of patients with schizophrenia and schizotypal and delusional disorders is highly affected by the cohort. The prevalence of patients with mood disorders displayed an increase in trends over the cohorts but particularly in the younger age groups. Similar results were observed in patients with mood disorders and neurotic, stress-related, and somatoform disorders.

Table 3 shows the age-adjusted number of patients with schizophrenia and schizotypal and delusional disorders, mood disorders, and neurotic, stress-related, and somatoform disorders in men and women per 1,000 persons. The age-adjusted prevalence of patients with schizophrenia and schizotypal and delusional disorders increased from 1999 to 2017 in both men and women. The age-adjusted prevalence of patients with mood disorders and neurotic, stress-related, and somatoform disorders also increased over the analyzed periods, and the degree of increase was higher than that of schizophrenia and schizotypal and delusional disorders. The age-adjusted prevalence of patients with neurotic, stress-related, and somatoform disorders increased particularly in women.

Table 4 shows the results of APC analysis for each disease in men. We presented the result of birth cohorts from cohorts born in 1911-1915 to those in 1991-1995 by 5-year increments for visibility of the results. The age effect for schizophrenia and schizotypal and delusional disorders significantly increased from age groups of 20-24 to 45-49 years, and then decreased thereafter. There was a significant difference in the age effect between 45-49 years and 85-89 years. The period effect highlighted a slightly increasing trend, but there was not statistically significant difference among the effects. The cohort effect displayed a significant increasing trend from cohorts born in 1911-1915 to cohorts born in 1961-1965, and the estimate decreased in cohorts born in thereafter. Age effect for mood disorders significantly increased from the age group of 20-24 to the age group of 55-59 and also decreased thereafter. The period effect showed an increase approximately three times from 1999 to 2017, and there was a statistically significant difference between 1999 and 2017. The cohort effect decreased from cohort born in 1921-1925 to 1946-1950, and showed an increasing trend afterwards. The results of patients with diagnoses neurotic, stress-related, and somatoform disorders were relatively similar

to those of mood disorders.

Table 5 shows the results of APC analysis for each disease in women. The age effect for schizophrenia and schizotypal and delusional disorders significantly increased from age group of 20–24 to the group aged 55–59, and the age effects for older ages were significantly lower than the age group of 55–59. Although there was a sudden decline in 2011, the period effect showed an overall increasing trend over the analyzed period. The cohort effect significantly increased from cohort born in 1911–1915 to 1961–1965, and it decreased thereafter. The age effect for mood disorders significantly increased from the age group of 20–24 to the age group of 65–69, and decreased afterwards. Also, the period effect significantly increased from 1999 to 2017. The cohort effect significantly decreased from cohort born in 1921–1925 to 1951–1955, and started increasing after that. Although the results of patients with neurotic, stress-related, and somatoform disorders were relatively similar to those of mood disorders, the degree of increase for the cohort effect was larger for neurotic, stress-related, and somatoform disorders, and there was a statistically significance difference between cohorts born in 1951–1955 and 1991–1995.

Discussion

We analyzed the data of the Patient Survey for revealing the trends of age, period, and cohort effects for prevalence of each disease. As a result of APC analysis, a significant increase of prevalence in the middle ages and a significant decrease of the prevalence in older ages were observed in all the diseases. However, the peak for age effects of mood disorders and neurotic, stress-related, and somatoform disorders were seen to be later for women compared to men. Also, the significant increase of the period effects was observed for mood disorders and neurotic, stress-related, and somatoform disorders during the analyzed periods. Although a significant increase of the cohort effects until the middle of the analyzed cohorts and a decrease of the effects afterwards was observed for schizophrenia and schizotypal and delusional disorders, a reverse phenomenon was observed for mood disorders and neurotic, stress-related, and somatoform disorders. The trend for each effect in mood disorders and neurotic, stress-related, and somatoform disorders were relatively similar.

Regarding age effect for schizophrenia and schizotypal and delusional disorders, it has been reported that patients with schizophrenia are more likely to have type 2 diabetes or cardiovascular diseases [17,18], and the life expectancy of patients with schizophrenia is shorter than that of the general population [19,20]. Therefore, there is a possibility that the rapid decline of age effects signify that the mortality rate for schizophrenia in the older age groups is relatively high. The peaks for age effect were also seen to be different among the sexes, and this is considered to be in relation to the sex difference for the onset age of schizophrenia, as the onset is generally earlier for men [21,22]. Regarding mood disorders, the life expectancy of patients with unipolar depression or bipolar affective disorder is also known to be generally shorter than in the general population [20,23] and is reflected as such in this analysis. The peak of age effect for mood disorders and neurotic, stress-related, and somatoform disorders was considered to be near the 40s for men, which may be due to the fact that social stress in these age groups is considered to be relatively high because social stress is a major risk factor for depression [24]. The peak age of onset for depression in women is considered to be during the perinatal period and during menopause [25], and onset after menopause is considered to affect the result of the later peak age for women.

Regarding period effects, a significant increase of the prevalence with mood disorders and neurotic, stress-related, and somatoform disorders may be related to an increase over the past few years in public awareness for these disorders. It is interesting to note that words like “stress” and “depressive” have come to be frequently used in daily conversation in Japan. According to a previous study [26], the increase in diseases over the years may be due to the increase in mental health service usage. However, there is a possibility that the prevalence of patients with mood disorders and neurotic, stress-related, and somatoform disorders are actually increasing particularly in young ages because as described below, the trends of the cohort effects were relatively consistent with that of suicide. Also, depression was shown to be associated with lifestyle-related diseases such as diabetes and obesity [27,28], and the consultation rate of lifestyle-related diseases is also currently on the rise in Japan [1]. Regarding the similarity of mood disorders and neurotic, stress-related, and somatoform disorders, the risk factors for these diseases are relatively common [29,30]. It is already shown that

comorbidity of major depression and anxiety disorder is high [31], and that there is an overlap of these disorders in patients.

Regarding the cohort effect for prevalence of schizophrenia and schizotypal and delusional disorders, the decrease of the prevalence in the younger age groups as shown in Table 1 and 2 is considered to have caused the decrease in cohort effect. One possible reason for the decrease of the cohort effect is the discharge of patients with psychiatric disorders as is currently ongoing in Japan, which has led to a decrease in patients who are hospitalized with psychiatric disorders [1]. According to the Patient Survey [1], the mean length of stay for patients with schizophrenia and schizotypal and delusional disorders is much longer than patients with other diseases, and the number of hospitalized patients with schizophrenia and schizotypal and delusional disorders is also declining. This may be due to the trend of the cohort effect. There is also a possibility that the incidence of schizophrenia is actually decreasing in more recent born cohorts as reported in recent reports citing a decrease in incidences of schizophrenia from the 1960s in other countries [32]. It is also possible that the recovery rate for young patients with schizophrenia may be increasing owing to the development of psychiatric drugs.

Regarding the cohort effect for prevalence of patients with mood disorders and neurotic, stress-related, and somatoform disorders, the increase of prevalence in the younger age groups is relatively high, and this is considered to have affected the trend of the cohort effect. According to a study that conducted an APC analysis for suicide rate in Japanese individuals [33], the cohort effect for suicide rates also tended to increase from approximately 1950 for women and that from approximately 1960 for men. Therefore, the trend of cohort effect for patients with mood disorders and neurotic, stress-related, and somatoform disorders is considered to have an effect on the trend of suicide. Social insecurity may be a possible reason for the increase in cohort effect for the suicide rate [33], and it was pointed out that the younger cohorts in Japan are in relative poverty among developed countries in contrast with cohorts born in approximately 1951 [33,34]. Stagnation of Japanese economy and an increase in precarious jobs from the late 20th Century are pointed out to be related to this phenomenon [33]. Socioeconomic status was shown to be related to depression in a previous study [35],

and there are reports indicating the association between precarious job and psychological distress in Japan [36,37]. Therefore, social insecurity in the younger age group may be a factor affecting the trend of cohort effects for mood disorders and neurotic, stress-related, and somatoform disorders. Additionally, the employment rate in women was seen as rapidly increasing over the cohorts, and this may have affected variability of the cohort effect in women. Another factor for the increase of the cohort effect may be due to the Mental Health Act which was enacted in 1950 as it required each prefecture to establish a public psychiatric hospital. This may have led to an increase in the consultation rates of patients with depression and/or anxiety disorder over the cohorts.

The study is not without its limitations. As mentioned in the Methods section, the Patient Survey displays the estimated total number of patients in increments of 1000; therefore, it does not present the actual number of patients. In addition, the number of patients reflects the consultation rate rather than the prevalence of a disease. An epidemiological study needs to be conducted in the future to assess the true prevalence of the diseases. Moreover, a validity of estimated number of patients in the Patient Survey has not been confirmed, and the validity of the calculation method of the estimated total number of patients needs to be examined immediately. Also, only the data of patients who were treated in a disease in the date of the Survey are counted in the calculation of the estimated number of patients [38]. Therefore, a patient with a psychiatric disease who consulted a hospital for a disease, such as cancer and cardiovascular diseases is not counted in the number of patients with the psychiatric disease. Also, patients with 2 or more psychiatric disorders can be treated as a patient with either disease. Therefore, the decrease of the age effects for each disease possibly means that prevalence of the psychiatric patients with other diseases increases with age. Furthermore, this study specifically focused on the number of patients with schizophrenia and schizotypal and delusional disorders, mood disorders and neurotic, stress-related, and somatoform disorders, and was not able to focus on particular types of disease such as schizophrenia or depression, which would also be worthwhile to explore. On the other hand, the strength of the Patient Survey is that more than 10,000 medical institutes are examined every survey year in the survey [38], and the coverage of the survey is larger than any other survey for psychiatric disease in

Japan.

Conclusions

As a result of the APC analysis, the peaks of age effect were different among sexes and diseases. The period effects for all the diseases showed an increase in trends over the analyzed years. Although the cohort effect for schizophrenia and schizotypal and delusional disorders started to decrease from approximately the 1960s, the cohort effects for mood disorders and neurotic, stress-related, and somatoform disorders started to increase from around the 1950s. The tuning points of the cohort effects for these diseases were relatively similar to that of suicide mortality rate in Japan. In addition, an increase in social insecurity in younger cohorts had been pointed out as a factor for the increase of the cohort effect of suicide mortality rate in a previous study.

Therefore, there is a possibility that an increase in psychological stress associated with change in social environment and public awareness of the diseases affected the trends of the period and cohort effects for mood disorders and neurotic, stress-related, and somatoform disorders.

Acknowledgements

Enago has proofread the manuscript.

Funding

Not applicable

Conflicts of Interest

There are no potential conflicts of interest to declare.

Availability of data and material

The data used in this study can be downloaded from the website of Japan's government statistics.

275

276 **Code availability**

277 The software code of APC analysis used in this study can be shared upon request.

278

279 **Ethics approval**

280 Not applicable because we used data that are publicly available.

281

282 **Consent to participate**

283 Not applicable

284

285 **Consent for publication**

286 Not applicable

287

288 **Authors' contributions**

289 Conceptualization: TO. Data curation: TO. Formal analysis: TO. Methodology: TO. Funding acquisition: None.

290 Writing- original draft: TO. Writing - review & editing: TO.

291

292 **REFERENCES**

293 1. Ministry of Health, Labour and Welfare of Japan. The Patient Survey. [https://www.e-stat.go.jp/stat-](https://www.e-stat.go.jp/stat-search/files?page=1&toukei=00450022&tstat=000001031167)

294 [search/files?page=1&toukei=00450022&tstat=000001031167](https://www.e-stat.go.jp/stat-search/files?page=1&toukei=00450022&tstat=000001031167). Accessed 8 May 2020 (Japanese)

295 2. Ministry of Health, Labour and Welfare of Japan. (2017) Overview of national medical expenses 2017

296 <https://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/17/index.html>. Accessed 8 May 2020 (Japanese)

297 3. Sado M, Inagaki A, Koreki A, Knapp M, Kissane L, Mimura M, Yoshimura K. (2013) The cost of

298 schizophrenia in Japan. *Neuropsychiatr Dis Treat* 9:787–798

4. Nishi D, Susukida R, Usuda K, Mojtabai R, Yamanouchi Y. (2018) Trends in the prevalence of psychological distress and the use of mental health services from 2007 to 2016 in Japan. *J Affect Disord* 15;239:208-213.
5. Kawakami N, Shimizu H, Haratani T, Iwata N, Kitamura T. (2004) Lifetime and 6-month prevalence of DSM-III-R psychiatric disorders in an urban community in Japan. *Psychiatry Res* 121:293–301
6. Nakane Y, Ohta Y, Radford MH. Epidemiological studies of schizophrenia in Japan. (1992) *Schizophr Bull.* 18:75-84
7. Smith TR, Wakefield J. (2016) A Review and Comparison of Age–Period–Cohort Models for Cancer Incidence. *Statistical Science* 31:591-610
8. Ma E, Iso H, Takahashi H, Yamagishi K, Tanigawa T. (2008) Age–Period–Cohort Analysis of Mortality due to Ischemic Heart Disease in Japan, 1955 to 2000. *Circulation Journal* 72:966-972
9. Wang Z, Bao J, Yu C, Wang J, Li C. (2015) Secular Trends of Breast Cancer in China, South Korea, Japan and the United States: Application of the Age-Period-Cohort Analysis. *Int J Environ Res Public Health* 12:15409-15418
10. Wickramaratne PJ, Weissman MM, Leaf PJ, Holford TR. (1989) Age, period and cohort effects on the risk of major depression: results from five United States communities. *J Clin Epidemiol* 42:333–343
11. Takei N, Lewis G, Sham PC, Murray RM. (1996) Age-period-cohort analysis of the incidence of schizophrenia in Scotland. *Psychol Med* 26:963–973
12. Keyes KM, Nicholson R, Kinley J, Raposo S, Stein M, Goldner E, Sareen J. (2014) Age, period, and cohort effects in psychological distress in the United States and Canada. *Am J Epidemiol* 179:1216–1227
13. Ministry of Health, Labour and Welfare. Frequently asked questions about the Patient Survey. <https://www.mhlw.go.jp/toukei/list/dl/10-20qa.pdf>. Accessed 22 October 2020.
14. Ministry of Health, Labour and Welfare of Japan. The Vital Statistics. <https://www.e-stat.go.jp/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&tclass1=000001053058&tclass2=000001053061&tclass3=000001053072>. Accessed 8 May 2020

324 15. Stan Development Team. (2019) RStan: the R interface to Stan. R package version 2.19.2. [http://mc-](http://mc-stan.org/)
325 [stan.org/](http://mc-stan.org/). Accessed 8 May 2020

326 16. R Core Team. (2018) R: A language and environment for statistical computing. R Foundation for
327 Statistical Computing, Vienna, Austria. <https://www.R-project.org/>. Accessed 8 May 2020

328 17. Mamakou V, Thanopoulou A, Gonidakis F, Tentolouris N, Kontaxakis V. (2018) Schizophrenia and type
329 2 diabetes mellitus. *Psychiatriki* 29:64–73

330 18. Hennekens CH, Hennekens AR, Hollar D, Casey DE. (2005) Schizophrenia and increased risks of
331 cardiovascular disease. *Am Heart J* 150:1115–1121

332 19. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. (2017) Years of potential life lost and life expectancy
333 in schizophrenia: a systematic review and meta-analysis. *Lancet Psychiatry* 4:295–301

334 20. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder.
335 (2011) *Schizophr Res* 131:101-104

336 21. Eranti SV, MacCabe JH, Bundy H, Murray RM. (2013) Gender difference in age at onset of
337 schizophrenia: a meta-analysis. *Psychol Med* 43:155–167

338 22. Abel KM, Drake R, Goldstein JM. (2010) Sex differences in schizophrenia. *Int Rev Psychiatry* 22:417–
339 428

340 23. Laursen TM, Musliner KL, Benros ME, Vestergaard M, Munk-Olsen T. (2016) Mortality and life
341 expectancy in persons with severe unipolar depression. *J Affect Disord* 193:203-207

342 24. Kendler KS, Karkowski LM, Prescott CA. (1999) Causal relationship between stressful life events and the
343 onset of major depression. *Am J Psychiatry* 156:837–841

344 25. Takamatsu K, Kasuga M, Makita K, Nozawa S. (2004) Evaluation of depressive conditions among
345 Japanese patients at a menopause clinic. *J Obstet Gynaecol Res* 30:42-47

346 26. Nishi D, Ishikawa H, Kawakami N. (2019) Prevalence of mental disorders and mental health service use
347 in Japan. *Psychiatry Clin Neurosci* 73:458–465

27. Hidese S, Asano S, Saito K, Sasayama D, Kunugi H. (2018) Association of depression with body mass index classification, metabolic disease, and lifestyle: A web-based survey involving 11,876 Japanese people. *J Psychiatr Res* 102:23–28
28. Katon WJ. (2008) The comorbidity of diabetes mellitus and depression. *Am J Med* 121(11 Suppl 2):S8–S15
29. Jacobson NC, Newman MG. (2017) Anxiety and depression as bidirectional risk factors for one another: A meta-analysis of longitudinal studies. *Psychol Bull* 143:1155-1200
30. Vink D, Aartsen MJ, Schoevers RA. (2008) Risk factors for anxiety and depression in the elderly: a review. *J Affect Disord* 106:29-44
31. Hirschfeld RM. (2001) The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care. *Prim Care Companion J Clin Psychiatry* 3:244–254
32. Warner R. (1995) Time trends in schizophrenia: changes in obstetric risk factors with industrialization. *Schizophr Bull* 21:483–500
33. Kino S, Jang SN, Gero K, Kato S, Kawachi I. (2019) Age, period, cohort trends of suicide in Japan and Korea (1986-2015): A tale of two countries. *Soc Sci Med* 235:112385
34. Abe K. (2012) Poverty and social exclusion of women in Japan. *Jpn. J. Soc. Secur. Pol* 9:61-82
35. Everson SA, Maty SC, Lynch JW, Kaplan GA. (2002) Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. *J Psychosom Res* 53:891-895
36. Takahashi T, Hori D, Ikeda T, Ikeda Y, Shiraki N, Andrea CS, Ohtaki Y, Doki S, Oi Y, Sasahara S, Matsuzaki I (2019). Non-Regular Employment Status Is Associated with Psychological Distress among Young Researchers: A Cross-Sectional Study in Tsukuba, Japan. *Tohoku J Exp Med* 249:57-64.
37. Kachi Y, Otsuka T, Kawada T (2014). Precarious employment and the risk of serious psychological distress: a population-based cohort study in Japan. *Scand J Work Environ Health* 40:465-72.
38. Ministry of Health, Labour and Welfare. The Patient Survey. <https://www.mhlw.go.jp/toukei/list/10-20.html>. Accessed 22 October 2020.

373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427

Table 1. Estimated number of patients with schizophrenia and schizotypal and delusional disorders, mood disorders, and neurotic, stress-related, and somatoform disorders by age groups (Unit: thousand persons) .

	20– 24	25– 29	30– 34	35– 39	40– 44	45– 49	50– 54	55– 59	60– 64	65– 69	70– 74	75– 79	80– 84	85– 89
Male schizophrenia, schizotypal and delusional disorders														
1999	12	26	29	35	33	46	47	32	26	22	10	4	2	1
2002	15	28	41	38	38	41	48	35	29	20	14	5	3	1
2005	11	26	38	41	37	36	42	41	30	24	15	8	3	1
2008	13	18	33	42	40	43	41	51	39	26	17	11	5	1
2011	14	17	27	41	43	41	33	37	40	23	16	11	5	2
2014	8	16	26	37	41	44	38	37	39	30	18	13	6	2
2017	9	12	22	31	46	50	40	42	38	39	23	14	6	3
Male mood [affective] disorders														
1999	4	8	13	12	15	16	15	16	15	21	12	7	2	1
2002	4	17	18	22	24	22	28	22	21	21	20	14	5	1
2005	9	22	34	34	40	32	32	31	28	21	22	15	7	1
2008	11	14	35	44	43	41	37	34	32	27	26	20	12	3
2011	11	19	26	41	45	40	38	38	32	20	24	21	10	3
2014	8	24	26	36	52	50	38	43	36	40	22	22	9	7
2017	12	19	32	41	53	56	63	48	35	41	32	25	20	6
Male neurotic, stress-related and somatoform disorders														
1999	9	13	15	16	13	15	18	12	12	14	11	7	3	1
2002	7	15	20	22	12	14	14	15	10	12	13	9	3	2
2005	9	14	24	24	14	18	17	22	14	11	12	8	4	1
2008	8	14	19	22	20	17	19	17	16	12	13	11	6	3
2011	15	16	17	18	26	19	16	16	14	16	13	10	3	3
2014	9	19	18	32	23	27	20	17	24	17	16	12	9	3
2017	14	15	26	22	33	30	30	18	14	27	10	14	11	4
Female schizophrenia, schizotypal and delusional disorders														
1999	12	21	30	28	25	40	42	44	30	25	18	10	4	2
2002	17	25	32	33	25	35	52	39	37	33	20	12	5	3
2005	12	21	32	38	38	35	44	42	42	36	22	16	8	3
2008	15	22	29	32	37	35	39	48	43	35	32	18	10	5
2011	9	17	24	34	33	31	31	35	41	31	28	21	10	7
2014	11	14	22	32	44	40	39	41	41	41	36	20	17	7
2017	6	13	23	26	39	38	40	42	42	53	30	26	15	9
Female mood [affective] disorders														
1999	7	11	17	14	22	18	24	28	26	38	32	24	10	4
2002	14	19	38	32	29	33	38	47	47	47	48	39	20	7
2005	23	34	49	45	47	39	35	53	49	50	57	52	30	11
2008	25	35	47	55	53	52	42	55	58	62	62	56	28	12
2011	16	33	36	60	57	43	41	39	54	45	44	49	38	18
2014	17	31	40	63	78	60	57	45	56	68	60	47	39	19
2017	24	33	44	47	78	82	70	58	62	75	64	62	46	21
Female neurotic, stress-related and somatoform disorders														
1999	9	19	19	19	17	18	22	21	26	29	24	15	6	4
2002	11	22	31	25	24	23	28	27	25	31	25	20	8	4
2005	20	25	35	44	29	21	26	36	28	25	36	20	14	4
2008	13	24	27	40	38	28	25	29	31	31	31	24	16	5
2011	17	28	34	34	37	30	27	19	26	21	24	23	14	7
2014	17	26	30	40	49	46	37	36	35	35	38	23	22	9
2017	19	30	42	53	61	61	54	34	35	42	33	27	21	12

Table 2. Number of patients with schizophrenia and schizotypal and delusional disorders, mood disorders, and neurotic, stress-related, and somatoform disorders by age groups per 1,000 persons.

	20– 24	25– 29	30– 34	35– 39	40– 44	45– 49	50– 54	55– 59	60– 64	65– 69	70– 74	75– 79	80– 84	85– 89
Male schizophrenia, schizotypal and delusional disorders														
1999	2.7	5.3	6.7	8.9	8.4	9.8	9.6	7.4	7.1	6.7	3.9	2.7	2.3	2.2
2002	3.7	6.0	8.7	9.3	9.8	10.1	9.1	8.3	7.4	5.7	5.0	2.6	3.1	2.0
2005	3.0	6.3	7.8	9.4	9.2	9.4	9.6	8.1	7.2	6.8	4.9	3.5	2.5	1.8
2008	3.7	4.8	7.4	8.8	9.6	11.2	10.6	10.6	9.0	6.8	5.3	4.5	3.2	1.6
2011	4.4	4.8	6.7	8.4	9.3	10.4	8.7	9.0	7.7	6.2	4.8	4.1	2.8	2.4
2014	2.6	4.8	7.0	8.5	8.4	10.3	9.8	9.8	8.9	6.8	4.9	4.7	3.1	1.9
2017	3.0	3.9	6.3	7.9	9.8	10.6	9.9	11.2	10.0	8.2	6.4	4.7	2.8	2.6
Male mood [affective] disorders														
1999	0.9	1.6	3.0	3.1	3.8	3.4	3.1	3.7	4.1	6.4	4.7	4.7	2.3	2.2
2002	1.0	3.6	3.8	5.4	6.2	5.4	5.3	5.2	5.4	6.0	7.1	7.3	5.1	2.0
2005	2.4	5.3	7.0	7.8	9.9	8.3	7.3	6.1	6.7	5.9	7.2	6.6	5.7	1.8
2008	3.1	3.7	7.8	9.2	10.3	10.6	9.6	7.0	7.4	7.1	8.1	8.1	7.7	4.7
2011	3.5	5.3	6.5	8.4	9.7	10.1	10.1	9.3	6.2	5.4	7.2	7.9	5.7	3.6
2014	2.6	7.3	7.0	8.3	10.6	11.7	9.8	11.4	8.2	9.1	6.0	8.0	4.6	6.8
2017	3.9	6.2	9.1	10.5	11.2	11.9	15.6	12.8	9.2	8.6	8.9	8.3	9.3	5.1
Male neurotic, stress-related and somatoform disorders														
1999	2.0	2.6	3.5	4.1	3.3	3.2	3.7	2.8	3.3	4.3	4.3	4.7	3.5	2.2
2002	1.7	3.2	4.2	5.4	3.1	3.5	2.7	3.5	2.6	3.4	4.6	4.7	3.1	3.9
2005	2.4	3.4	4.9	5.5	3.5	4.7	3.9	4.3	3.4	3.1	3.9	3.5	3.3	1.8
2008	2.3	3.7	4.3	4.6	4.8	4.4	4.9	3.5	3.7	3.1	4.1	4.5	3.8	4.7
2011	4.7	4.5	4.2	3.7	5.6	4.8	4.2	3.9	2.7	4.3	3.9	3.7	1.7	3.6
2014	2.9	5.8	4.9	7.4	4.7	6.3	5.2	4.5	5.5	3.9	4.4	4.4	4.6	2.9
2017	4.6	4.9	7.4	5.6	7.0	6.4	7.4	4.8	3.7	5.7	2.8	4.7	5.1	3.4
Female schizophrenia, schizotypal and delusional disorders														
1999	2.8	4.4	7.2	7.3	6.4	8.5	8.5	9.8	7.6	6.8	5.7	4.1	2.5	2.0
2002	4.5	5.5	7.0	8.2	6.6	8.7	9.8	8.9	8.9	8.5	5.9	4.4	2.7	2.6
2005	3.4	5.3	6.8	8.9	9.6	9.2	10.0	8.1	9.6	9.3	6.1	5.3	3.7	2.3
2008	4.5	6.1	6.7	6.9	9.1	9.2	10.1	9.7	9.4	8.4	8.6	5.6	4.0	3.3
2011	3.0	4.9	6.2	7.2	7.3	8.0	8.2	8.4	7.6	7.6	7.3	6.1	3.7	3.9
2014	3.8	4.4	6.2	7.6	9.3	9.5	10.2	10.8	9.0	8.7	8.5	5.7	5.8	3.5
2017	2.1	4.4	6.8	6.9	8.5	8.3	10.0	11.2	10.7	10.4	7.3	7.0	4.8	4.1
Female mood [affective] disorders														
1999	1.6	2.3	4.1	3.6	5.7	3.8	4.9	6.2	6.6	10.4	10.1	9.9	6.3	4.0
2002	3.7	4.2	8.3	8.0	7.6	8.2	7.2	10.8	11.3	12.2	14.2	14.3	10.7	6.1
2005	6.6	8.5	10.4	10.6	11.9	10.2	8.0	10.3	11.2	12.9	15.9	17.3	13.7	8.5
2008	7.5	9.7	10.9	11.8	13.0	13.7	10.9	11.1	12.7	14.9	16.6	17.4	11.3	7.9
2011	5.3	9.6	9.3	12.8	12.6	11.1	10.9	9.4	10.0	11.0	11.5	14.2	14.0	10.0
2014	5.8	9.8	11.2	15.1	16.4	14.3	14.9	11.8	12.3	14.4	14.2	13.5	13.4	9.4
2017	8.3	11.2	13.0	12.4	17.1	17.9	17.6	15.4	15.8	14.7	15.6	16.7	14.7	9.5
Female neurotic, stress-related and somatoform disorders														
1999	2.1	4.0	4.5	4.9	4.4	3.8	4.5	4.7	6.6	7.9	7.6	6.2	3.8	4.0
2002	2.9	4.8	6.8	6.2	6.3	5.7	5.3	6.2	6.0	8.0	7.4	7.3	4.3	3.5
2005	5.7	6.3	7.4	10.4	7.3	5.5	5.9	7.0	6.4	6.4	10.0	6.7	6.4	3.1
2008	3.9	6.6	6.2	8.6	9.3	7.4	6.5	5.9	6.8	7.4	8.3	7.5	6.4	3.3
2011	5.7	8.2	8.8	7.2	8.2	7.7	7.2	4.6	4.8	5.1	6.3	6.7	5.1	3.9
2014	5.8	8.2	8.4	9.6	10.3	11.0	9.7	9.4	7.7	7.4	9.0	6.6	7.5	4.4
2017	6.6	10.2	12.4	14.0	13.4	13.3	13.6	9.1	8.9	8.2	8.0	7.3	6.7	5.4

Table 3. Age-adjusted number of patients with diagnoses schizophrenia and schizotypal and delusional disorders, mood disorders, and neurotic, stress-related, and somatoform disorders per 1,000 persons.

Diseases types, sex and periods	Schizophrenia, schizotypal and delusional disorders		Mood [affective] disorders		Neurotic, stress-related and somatoform disorders	
	Men	Women	Men	Women	Men	Women
1999	6.80	6.64	3.29	5.18	3.33	4.80
2002	7.38	7.30	4.86	8.48	3.42	5.82
2005	7.26	7.62	6.63	10.49	3.89	6.91
2008	7.80	7.82	7.57	11.89	3.97	6.86
2011	7.17	6.72	7.42	10.39	4.20	6.73
2014	7.31	7.77	8.34	12.59	5.02	8.67
2017	7.65	7.66	9.78	14.43	5.55	10.64

Table 4. The result of APC analysis for each disease for men.

	Estimate of each effect (95% credible interval)		
	Schizophrenia, schizotypal and delusional disorders	Mood [affective] disorders	Neurotic, stress-related and somatoform disorders
Age effect			
20–24	0.562 (0.453, 0.710)	0.327 (0.176, 0.528)	0.655 (0.440, 0.911)
25–29	0.818 (0.675, 1.006)	0.642 (0.381, 0.974)	0.872 (0.629, 1.156)
30–34	1.111 (0.939, 1.326)	0.933 (0.609, 1.325)	1.069 (0.818, 1.371)
35–39	1.306 (1.131, 1.519)	1.152 (0.825, 1.531)	1.183 (0.947, 1.474)
40–44	1.350 (1.191, 1.533)	1.371 (1.059, 1.721)	1.123 (0.929, 1.353)
45–49	1.495 (1.342, 1.671)	1.428 (1.181, 1.706)	1.179 (1.009, 1.387)
50–54	1.450 (1.319, 1.596)	1.478 (1.267, 1.720)	1.172 (1.007, 1.370)
55–59	1.433 (1.305, 1.576)	1.477 (1.254, 1.734)	1.094 (0.934, 1.281)
60–64	1.348 (1.215, 1.493)	1.352 (1.114, 1.660)	1.016 (0.857, 1.214)
65–69	1.188 (1.051, 1.340)	1.329 (1.054, 1.750)	1.077 (0.894, 1.322)
70–74	0.954 (0.822, 1.102)	1.212 (0.909, 1.699)	1.069 (0.866, 1.356)
75–79	0.774 (0.645, 0.921)	1.120 (0.789, 1.688)	1.053 (0.816, 1.386)
80–84	0.625 (0.505, 0.764)	0.813 (0.536, 1.344)	0.861 (0.630, 1.151)
85–89	0.484 (0.379, 0.609)	0.522 (0.325, 0.924)	0.768 (0.544, 1.060)
Period effect			
1999	0.975 (0.897, 1.029)	0.530 (0.455, 0.635)	0.856 (0.756, 0.964)
2002	1.000 (0.952, 1.051)	0.762 (0.676, 0.869)	0.884 (0.797, 0.973)
2005	1.001 (0.960, 1.041)	0.997 (0.906, 1.101)	0.923 (0.845, 1.004)
2008	1.017 (0.988, 1.068)	1.184 (1.087, 1.290)	0.992 (0.916, 1.076)
2011	1.002 (0.964, 1.043)	1.130 (1.026, 1.242)	1.009 (0.921, 1.098)
2014	0.996 (0.945, 1.044)	1.262 (1.104, 1.425)	1.155 (1.045, 1.284)
2017	1.010 (0.952, 1.086)	1.471 (1.234, 1.715)	1.240 (1.091, 1.413)
Birth cohort effect			
1911–1915	0.749 (0.566, 1.000)	1.033 (0.514, 1.862)	1.035 (0.688, 1.579)
1916–1920	0.710 (0.550, 0.927)	0.937 (0.467, 1.574)	1.030 (0.709, 1.495)
1921–1925	0.725 (0.577, 0.922)	1.171 (0.677, 1.864)	1.067 (0.787, 1.523)
1926–1930	0.815 (0.671, 0.995)	1.156 (0.718, 1.727)	0.975 (0.723, 1.283)
1931–1935	0.918 (0.780, 1.085)	1.037 (0.694, 1.444)	0.971 (0.758, 1.233)
1936–1940	0.971 (0.844, 1.120)	0.871 (0.617, 1.149)	0.888 (0.697, 1.074)
1941–1945	0.994 (0.875, 1.124)	0.763 (0.582, 0.962)	0.851 (0.685, 1.014)
1946–1950	1.089 (0.975, 1.215)	0.743 (0.594, 0.906)	0.859 (0.708, 1.009)
1951–1955	1.180 (1.062, 1.319)	0.812 (0.679, 0.964)	0.884 (0.741, 1.025)
1956–1960	1.193 (1.072, 1.336)	0.939 (0.786, 1.129)	0.925 (0.780, 1.074)
1961–1965	1.229 (1.085, 1.398)	1.019 (0.827, 1.291)	0.986 (0.821, 1.170)
1966–1970	1.227 (1.062, 1.415)	1.040 (0.804, 1.407)	1.063 (0.880, 1.320)
1971–1975	1.193 (1.010, 1.403)	1.045 (0.764, 1.540)	1.033 (0.819, 1.309)
1976–1980	1.139 (0.938, 1.376)	1.040 (0.714, 1.686)	1.040 (0.796, 1.371)
1981–1985	1.050 (0.843, 1.291)	1.104 (0.709, 1.944)	1.091 (0.810, 1.536)
1986–1990	1.051 (0.817, 1.342)	1.269 (0.762, 2.532)	1.188 (0.856, 1.813)
1991–1995	0.948 (0.716, 1.227)	1.222 (0.681, 2.563)	1.195 (0.823, 1.892)

461 Table 5. The result of APC analysis for each disease for women.

	Estimate of each effect (95% credible interval)		
	Schizophrenia, schizotypal and delusional disorders	Mood [affective] disorders	Neurotic, stress-related and somatoform disorders
Age effect			
20–24	0.600 (0.437, 0.841)	0.414 (0.276, 0.614)	0.448 (0.276, 0.701)
25–29	0.793 (0.601, 1.061)	0.605 (0.428, 0.849)	0.724 (0.479, 1.065)
30–34	0.994 (0.784, 1.273)	0.833 (0.623, 1.108)	0.899 (0.640, 1.238)
35–39	1.090 (0.901, 1.331)	0.991 (0.789, 1.249)	1.118 (0.857, 1.444)
40–44	1.138 (0.979, 1.330)	1.225 (1.024, 1.472)	1.209 (0.988, 1.470)
45–49	1.225 (1.089, 1.379)	1.223 (1.065, 1.409)	1.237 (1.074, 1.423)
50–54	1.337 (1.217, 1.469)	1.246 (1.107, 1.401)	1.365 (1.228, 1.516)
55–59	1.360 (1.237, 1.495)	1.344 (1.194, 1.512)	1.344 (1.206, 1.493)
60–64	1.285 (1.143, 1.444)	1.396 (1.206, 1.618)	1.376 (1.189, 1.601)
65–69	1.238 (1.061, 1.438)	1.446 (1.207, 1.738)	1.339 (1.098, 1.647)
70–74	1.084 (0.889, 1.311)	1.369 (1.090, 1.730)	1.332 (1.031, 1.747)
75–79	0.907 (0.709, 1.146)	1.265 (0.951, 1.692)	1.037 (0.756, 1.446)
80–84	0.729 (0.543, 0.966)	0.927 (0.654, 1.291)	0.804 (0.549, 1.201)
85–89	0.670 (0.476, 0.930)	0.594 (0.399, 0.872)	0.547 (0.352, 0.868)
Period effect			
1999	0.908 (0.817, 1.004)	0.505 (0.445, 0.571)	0.745 (0.651, 0.855)
2002	0.979 (0.908, 1.053)	0.842 (0.767, 0.923)	0.881 (0.797, 0.975)
2005	1.013 (0.958, 1.071)	1.078 (1.004, 1.159)	1.016 (0.945, 1.093)
2008	1.046 (0.995, 1.104)	1.179 (1.105, 1.258)	0.997 (0.940, 1.058)
2011	0.964 (0.905, 1.021)	1.068 (0.994, 1.148)	0.941 (0.876, 1.010)
2014	1.052 (0.976, 1.143)	1.237 (1.126, 1.363)	1.183 (1.068, 1.309)
2017	1.046 (0.953, 1.159)	1.401 (1.242, 1.581)	1.352 (1.176, 1.549)
Birth cohort effect			
1911–1915	0.600 (0.392, 0.928)	1.248 (0.774, 2.048)	1.183 (0.659, 2.087)
1916–1920	0.638 (0.439, 0.937)	1.267 (0.829, 1.957)	0.909 (0.531, 1.488)
1921–1925	0.827 (0.605, 1.154)	1.309 (0.905, 1.931)	1.088 (0.697, 1.676)
1926–1930	0.921 (0.703, 1.220)	1.227 (0.893, 1.700)	1.007 (0.680, 1.455)
1931–1935	1.046 (0.832, 1.323)	1.078 (0.823, 1.413)	1.041 (0.760, 1.412)
1936–1940	1.152 (0.954, 1.404)	0.869 (0.692, 1.084)	0.775 (0.589, 1.000)
1941–1945	1.174 (1.006, 1.375)	0.786 (0.649, 0.942)	0.694 (0.559, 0.849)
1946–1950	1.104 (0.965, 1.259)	0.712 (0.610, 0.829)	0.670 (0.573, 0.783)
1951–1955	1.188 (1.055, 1.341)	0.664 (0.571, 0.767)	0.635 (0.550, 0.732)
1956–1960	1.169 (1.032, 1.328)	0.763 (0.660, 0.876)	0.733 (0.630, 0.851)
1961–1965	1.238 (1.062, 1.449)	0.849 (0.712, 1.003)	0.902 (0.749, 1.089)
1966–1970	1.225 (1.013, 1.479)	0.939 (0.758, 1.161)	1.142 (0.903, 1.468)
1971–1975	1.126 (0.897, 1.409)	0.993 (0.766, 1.290)	1.110 (0.827, 1.511)
1976–1980	1.071 (0.816, 1.388)	1.049 (0.772, 1.435)	1.189 (0.832, 1.741)
1981–1985	1.027 (0.744, 1.393)	1.219 (0.846, 1.783)	1.514 (0.986, 2.404)
1986–1990	0.933 (0.644, 1.331)	1.238 (0.812, 1.908)	1.562 (0.955, 2.648)
1991–1995	0.797 (0.521, 1.183)	1.235 (0.769, 2.012)	1.597 (0.915, 2.903)